

Ref. No: 2570
Date: 18/05/26
Subject: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

REQUEST

1. Service Context & Care Pathway

- Does your Trust diagnose and/or treat patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?
- If yes, which clinical departments or specialties are responsible for CIDP diagnosis and management? (e.g., Neurology, Neurophysiology, Immunology, Specialist Neuromuscular Services)
- Does your Trust operate a specialist neuromuscular or neuroimmunology service?
If so, please provide a brief description (e.g., staffing, catchment area, referral pathways).

2. CIDP Patient Numbers

- How many patients with a confirmed diagnosis of CIDP are currently recorded within your Trust?
Please provide the most recent 12 month period available.
- If available, please provide the number of newly diagnosed CIDP patients in the same period.
- If diagnosis data are coded, please confirm which coding system is used (e.g., ICD 10, SNOMED CT).

3. CIDP Treatment With IVIg

- How many CIDP patients received intravenous immunoglobulin (IVIg) at your Trust in the most recent 12 month period?
- Please provide the number of IVIg treatment episodes administered to CIDP patients in that period.
- If available, please provide the total volume (grams) of IVIg used for CIDP during the same period.
- How many CIDP patients received IVIg vs SCIg in the most recent 12-month period?
- If SCIg is used, please provide the number of treatment episodes and total grams administered.
- If available, please provide typical dosing regimens used for CIDP (e.g., grams/kg and treatment intervals).
- If recorded, please provide the average number of IVIg cycles per CIDP patient per year.

4. Operational & Capacity Information

- Does your Trust have a formal protocol or clinical guideline for the diagnosis and management of CIDP?

If yes, please provide a copy or link.

- Does your Trust operate a waiting list for IVIg treatment?

If yes, please provide the current number of patients waiting and the average waiting time.

- Does your Trust participate in any regional or national neuromuscular networks relevant to CIDP?

- Does your Trust record adverse events or complications associated with IVIg administration in CIDP patients? If yes, please provide any available summary data.

5. Commissioning, Governance & Funding

- Which commissioning arrangements apply to CIDP treatment at your Trust?

(e.g., specialised commissioning, local ICB commissioning)

- Does your Trust use a prior approval or funding request process for IVIg in CIDP?

- Does your Trust participate in the National Immunoglobulin Database (NID)? If yes, do you routinely submit CIDP specific data?

RESPONSE

Please be advised there are no centrally held (or shared via Trust Intranet sites) procedural documents for CIDP.